Wavelength-Pharmaceuticals-Insert
X

Find Neurology Drugs in Phase II Clinical Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SAR442168

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 17, 2020

            Details:

            Study’s primary endpoint was met, demonstrating that the BTK inhibitor significantly reduced disease activity associated with multiple sclerosis (MS) as measured by magnetic resonance imaging.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SAR442168

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 06, 2020

            Details:

            Sanofi’s BTK inhibitor will be first disease-modifying therapy to address sources of multiple sclerosis damage in the brain.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Vidofludimus calcium anhydrous

            Therapeutic Area: Neurology Product Name: IMU-838

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 02, 2020

            Details:

            The study achieved all primary and key secondary endpoints. study met its primary endpoint, demonstrating a statistically significant reduction in the cumulative number of combined unique active magnetic resonance imaging (MRI) lesions

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Bryostatin 1

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Neurotrope

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement July 30, 2020

            Details:

            Neurotrope has entered into a services agreement with Worldwide Clinical Trials to support site recruitment and activation for the Company's ongoing Phase 2 study of bryostatin-1 in the treatment of moderately severe Alzheimer's disease.

            Santa Lucia Foundation

            • Development Update

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Rotigotine

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 15, 2020

            Details:

            Rotigotine improved executive function, which helps patients with key cognitive tasks, such as reasoning, judgment, working memory, and orientation. It also improved their ability to complete routine daily activities.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IRL752

            Therapeutic Area: Neurology Product Name: IRL752

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 09, 2020

            Details:

            IRL752 is a drug candidate in clinical Phase II and is in development by IRLAB for the treatment of impaired balance (postural dysfunction) and falls in Parkinson's disease (PD-Falls).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ANVS401

            Therapeutic Area: Neurology Product Name: ANVS401

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 07, 2020

            Details:

            Annovis Bio has received clearance from the Central Institutional Review Board to launch its Phase 2 clinical trial in patients with early PD and early AD. The two-part study aims to treat a net number of 68 PD and AD patients with Annovis' lead drug, ANVS401 for 4 weeks.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Pepinemab

            Therapeutic Area: Neurology Product Name: VX15/2503

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 07, 2020

            Details:

            The data from Cohort A suggest that pepinemab can improve metabolic activity in the brain as detected by FDG-PET imaging, a biomarker that correlates with cognitive decline in other neurodegenerative diseases.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MSC-NTF cells

            Therapeutic Area: Neurology Product Name: NurOwn

            Highest Development Status: Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 01, 2020

            Details:

            The 52-week, open-label, proof-of-concept clinical trial is designed to evaluate NurOwn® in 40 participants with prodromal to mild AD.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ROPIVACAINE HYDROCHLORIDE

            Therapeutic Area: Neurology Product Name: PRF-110

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Maxim Group LLC

            Deal Size: $25.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering June 30, 2020

            Details:

            The company's lead candidate and first product, PRF-110, is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. Company plans to initiate two Phase 3 trials for PRF-110 soon after the closing of this offering.

            PharmaCompass